ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $103.43 Consensus Price Target from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average rating of “Moderate Buy” by the nine ratings firms that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $103.4286.

ANIP has been the topic of several analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays began coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective on the stock. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th.

More ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat estimates — record Q4 revenue of ~$247.1M and adjusted EPS of $2.33, with GAAP net income returning to positive versus a loss a year earlier. ANI Pharmaceuticals Reports Record Fourth-Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Rare Disease momentum — Cortrophin® Gel sales surged (~87.6% Q/QY) and management expects continued strong growth; company reiterated FY‑2026 revenue guidance ($1.055–$1.115B) and material upside for Cortrophin. ANI Pharmaceuticals Reports Record Quarterly and Full Year Revenue Growth
• Positive Sentiment: Strong profitability metrics and cash flow — adjusted non‑GAAP EBITDA grew materially year‑over‑year and the company generated significant operating cash flow in 2025. ANI Slide Deck / Press Materials
• Neutral Sentiment: Management hosted an earnings call and published slides/transcript — useful for color on commercialization plans (e.g., Rare Disease salesforce expansion and gout indication focus). ANI 2025 Q4 — Earnings Call Presentation ANI Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst/coverage context — several firms maintain bullish price targets and the quarter gives analysts data points to model Cortrophin growth into 2026. ANI Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Non‑GAAP gross margin compressed vs. prior year (down to ~59.6%) largely because of higher mix of royalty‑bearing products and lower Brands sales — margin pressure is a key sensitivity for valuation. Record Quarterly and Full Year Revenue Growth
• Negative Sentiment: Brands revenue fell significantly (Q4 Brands down ~38% Y/Y) and SG&A increased as the company invests in Rare Disease commercialization — increased costs plus mix shifts may temper near‑term margins. ANI Reports Record Fourth-Quarter and Full Year 2025 Results
• Negative Sentiment: Leverage and insider/institutional flows — the company carries significant outstanding debt (~$629M) and data shows recent insider sales and notable institutional position changes, which can amplify downside risk or create selling pressure. Quiver Quant Summary (includes insider/institutional notes)
• Negative Sentiment: Market reaction: several outlets noted ANIP shares fell early despite the beat — suggests some investors are locking gains or focusing on the margin/debt/stock‑holder flows rather than headline growth. ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%

ANI Pharmaceuticals Trading Down 4.2%

Shares of ANI Pharmaceuticals stock opened at $73.90 on Wednesday. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals has a 12-month low of $56.71 and a 12-month high of $99.50. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of 45.34 and a beta of 0.50. The firm’s 50-day moving average price is $80.19 and its two-hundred day moving average price is $86.39.

Insider Transactions at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total transaction of $42,165.00. Following the completion of the sale, the vice president directly owned 74,374 shares of the company’s stock, valued at $6,271,959.42. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Krista Davis sold 1,730 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $77.99, for a total transaction of $134,922.70. Following the completion of the sale, the senior vice president owned 49,263 shares in the company, valued at $3,842,021.37. This represents a 3.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 13,459 shares of company stock valued at $1,066,611. 11.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its holdings in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 237 shares during the period. Newbridge Financial Services Group Inc. lifted its position in shares of ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after acquiring an additional 400 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of ANI Pharmaceuticals in the fourth quarter worth $48,000. Finally, State of Wyoming bought a new position in shares of ANI Pharmaceuticals in the second quarter worth $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.